{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:57:36Z","timestamp":1784033856197,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jpba.2024.116012","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T01:48:48Z","timestamp":1707270528000},"page":"116012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Absorption, distribution, metabolism and excretion of linaprazan glurate in rats"],"prefix":"10.1016","volume":"242","author":[{"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingsheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116012_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1368-5031.2005.00517.x","article-title":"Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases","volume":"59","author":"Robinson","year":"2005","journal-title":"Int. J. Clin. Pr."},{"key":"10.1016\/j.jpba.2024.116012_bib2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s10620-014-3104-8","article-title":"Gastric acid-dependent diseases: a twentieth-century revolution","volume":"59","author":"Sachs","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jpba.2024.116012_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000505204","article-title":"Pharmacological approach to gastric acid suppression: past, present, and future","volume":"38","author":"Herszenyi","year":"2020","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jpba.2024.116012_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pa.35.040195.001425","article-title":"The pharmacology of the gastric acid pump: the H+,K+ ATPase","volume":"35","author":"Sachs","year":"1995","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"10.1016\/j.jpba.2024.116012_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/13543776.2013.741121","article-title":"H+\/K+-ATPase inhibitors: a patent review","volume":"23","author":"Li","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jpba.2024.116012_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10620-006-9156-7","article-title":"Proton pump inhibitors: effective first-line treatment for management of dyspepsia","volume":"52","author":"Peura","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jpba.2024.116012_bib7","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2165\/00003495-200363240-00004","article-title":"Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know","volume":"63","author":"Robinson","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116012_bib8","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12325-016-0345-2","article-title":"Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)","volume":"33","author":"Otake","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jpba.2024.116012_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/17425255.2022.2098107","article-title":"An update on drug\u2013drug interactions associated with proton pump inhibitors","volume":"18","author":"Ben Ghezala","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2024.116012_bib10","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.3748\/wjg.v11.i34.5259","article-title":"Role of potassium in acid secretion","volume":"11","author":"Geibel","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jpba.2024.116012_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.jpba.2024.116012_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker","volume":"25","author":"Mori","year":"2019","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.jpba.2024.116012_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","article-title":"Vonoprazan: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116012_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10620-017-4866-6","article-title":"Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases","volume":"63","author":"Yang","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jpba.2024.116012_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.jpba.2024.116012_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","article-title":"A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease","volume":"103","author":"Dent","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jpba.2024.116012_bib17","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","article-title":"A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis","volume":"5","author":"Kahrilas","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpba.2024.116012_bib18","doi-asserted-by":"crossref","first-page":"G838","DOI":"10.1152\/ajpgi.00120.2006","article-title":"Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands","volume":"291","author":"Kirchhoff","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jpba.2024.116012_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bcp.2006.09.020","article-title":"Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase","volume":"73","author":"Gedda","year":"2007","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.jpba.2024.116012_bib20","article-title":"Oral formulation of X842","author":"Andersson Kjell","year":"2021","journal-title":"WIPO, WO 2021\/089580 A1"},{"key":"10.1016\/j.jpba.2024.116012_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(18)31174-0","article-title":"Sa1093 - a first-in-human, open-label, healthy volunteer study of the new P-Cab X842 demonstrating 24H acid control for treatment of acid related diseases","volume":"154","author":"Unge","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpba.2024.116012_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122915","article-title":"Absorption, distribution, metabolism, and excretion of [14C]NBP (3-n-butylphthalide) in rats","volume":"1181","author":"Tian","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116012_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/00498254.2022.2030504","article-title":"Absorption, distribution, metabolism, and excretion of [14C]TPN729 after oral administration to rats","volume":"52","author":"Cheng","year":"2022","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2024.116012_bib24","unstructured":"S. Xu, R. Bian, X. Chen. Experimental Methodology of Pharmacology, Third Edition. People's Medical Publishing House, Fengtai District, Beijing, China, 2002: 1861."},{"key":"10.1016\/j.jpba.2024.116012_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2024.116012_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1015875800846","article-title":"Determination of the relative formation and elimination clearance of two major carbamazepine metabolites in humans: a comparison between traditional and pooled sample analysis","volume":"8","author":"Riad","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2024.116012_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jpha.2020.10.001","article-title":"Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota","volume":"11","author":"Zhang","year":"2021","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2024.116012_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/03602539808996322","article-title":"Sex-dependent metabolism of xenobiotics","volume":"30","author":"Mugford","year":"1998","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.jpba.2024.116012_bib29","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.115.064089","article-title":"Characterization of species differences in tissue diltiazem deacetylation identifies Ces2a as a rat-specific diltiazem deacetylase","volume":"43","author":"Kurokawa","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2024.116012_bib30","first-page":"G171","article-title":"Effects of sex steroid-hormones on gastric-emptying and gastrointestinal transit in rats","volume":"268","author":"Chen","year":"1995","journal-title":"Am. J. Physiol. -Gastr L"},{"key":"10.1016\/j.jpba.2024.116012_bib31","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/endo.139.4.5930","article-title":"Influence of sex differences on the renal secretion of organic anions","volume":"139","author":"Reyes","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.jpba.2024.116012_bib32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2174\/0113892002275839231205111422","article-title":"Pharmacokinetics, mass balance, tissue distribution and metabolism of [14C]101BHG-D01, a novel muscarinic receptor antagonist, in rats","volume":"24","author":"Gao","year":"2023","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2024.116012_bib33","article-title":"Development of a novel knockout model of retinitis pigmentosa using Pde6b--knockout Long-Evans rats.","volume":"9","author":"Yang","year":"2022","journal-title":"Front Med-Lausanne"},{"key":"10.1016\/j.jpba.2024.116012_bib34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jpha.2020.08.010","article-title":"Quantitative determination of D4-cystine in mice using LC-MS\/MS and its application to the assessment of pharmacokinetics and bioavailability","volume":"11","author":"Li","year":"2021","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2024.116012_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/00498254.2019.1678078","article-title":"Is genetic variability in carboxylesterase-1 and carboxylesterase-2 drug metabolism an important component of personalized medicine?","volume":"50","author":"Laizure","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2024.116012_bib36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/molecules13020412","article-title":"Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs","volume":"13","author":"Hosokawa","year":"2008","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2024.116012_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2024.116012_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17425255.2018.1420164","article-title":"Clinical implications of genetic variation in carboxylesterase drug metabolism","volume":"14","author":"Chen","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T21:41:16Z","timestamp":1715290876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":38,"alternative-id":["S0731708524000529"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116012","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorption, distribution, metabolism and excretion of linaprazan glurate in rats","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116012"}}